摘要
目的观察注射用重组改构人肿瘤坏死因子（rmh TNF）治疗恶性腹腔积液的疗效,并分析其影响因素。方法回顾2009-2013住院并行腹腔置管灌注rmh TNF治疗的70例恶性腹腔积液患者,随机分为2组：化疗＋rmh TNF组（rmh TNF组）40例,单纯化疗组30例。疗效评价分为完全缓解（CR）、部分缓解（PR）、无效（NC）,有效率=（CR＋PR）/总例数×100%;并进行治疗前后生存质量评分（Karnofsky评分）比较。毒性反应根据WHO抗癌药急性及亚急性毒性分级标准评估。结果 rmh TNF组有效率为77.5%（31/40）,单纯化疗组为53.3%（16/30）,组间差异有统计学意义（P=0.033）。Kamofsky评分rmh TNF组和单纯化疗治疗前分别为（74.40±4.12）和（73.30±2.35）;治疗后分别为（85.34±6.18）和（75.16±3.08）,两组比较差异有统计学意义（P〈0.05）。结论 rmh TNF与奈达铂化疗联合应用治疗恶性腹腔积液,有助于提高患者的近期有效率,改善患者的一般状况和生活质量。
Objective To observe the injection of recombinant mutant human tumor necrosis factor（recombinant mutant human tumor necrosis factor for injection）rmhTNF the efficacy of the treatment of malignant ascites and analyzes the influencing factors . Methods Retrospective 2009-2013 in our hospital inpatient concurrent abdominal tumor perfusion catheter rmhTNF treated 70 cases of malignant ascites patients were randomly divided into two groups：chemotherapy＋rmhTNF group（rmhTNF group ）40 cases ,30 patients with chemotherapy alone . Evaluation complete remission（CR）,partial response （PR）,inactive（NC）,efficiency =（CR ＋PR）/total number of cases × 100%;and quality of life before and after treatment score（Karnofsky score ） comparison. According to the WHO toxicity of anticancer drugs in acute and subacute toxicity grading criteria evaluation. Results rmhTNF group was 77.5%（31/40）,chemotherapy group was 53.3%（16/30 ）,there are differences between the two groups was statistically significant（P=0.033）. Kamofsky scores were rmhTNF before chemotherapy treatment group and（74.40±4.12）and（73.30±2.35）;were（85.34±6.18）and（75.16±3.08）after treatment ,the two groups there were significant differences（P〈0.05）. Conclusion rmhTNF combined with nedaplatin chemotherapy in treatment of malignant ascites , help to improve recent efficiency.
出处
《中国处方药》
2015年第6期9-10,共2页
Journal of China Prescription Drug
关键词
奈达铂
重组改构人肿瘤坏死因子
恶性腹水
Nedaplatin
Recombinant mutant human tumor necrosis factor
Malignant ascites
